Decrease of bone mineral density in Japanese patients with non-metastatic prostate cancer treated with androgen deprivation therapy
- 175 Downloads
The aim of this study was to conduct a cross-sectional survey of investigations related to the bone mineral density (BMD) of both non-metastatic prostate cancer (NMPC) patients who have not yet received androgen deprivation therapy (ADT) and patients receiving prolonged ADT in Japan. Japanese male patients with NMPC who received continuous ADT or who were planning to receive ADT were enrolled in this study. Lumbar spine and femoral neck BMD was measured using dual-energy X-ray absorptiometry (DEXA). To assess patient characteristics, we searched medical records and questionnaires to determine whether they had any factors that could possibly affect BMD. A total of 230 patients with a mean age of 76.6 ± 6.4 years were evaluated. Of these, 151 (65.7%) were receiving ADT, and 79 (34.4%) had not yet received ADT. The mean duration of ADT was 37.4 ± 30.7 months. DEXA showed that as the duration of ADT increased, lumbar spine and femoral neck BMD decreased gradually (p = 0.0005 and p = 0.0014, respectively). Stepwise regression analyses revealed that the duration of ADT was a significant variable of both lumbar spine and femoral neck BMD. Moreover, as the duration of ADT increased, the prevalence of osteoporosis increased statistically (p = 0.0002). This study showed that ADT negatively affected lumbar spine and femoral neck BMD. It also showed a progressive increase in the prevalence of osteoporosis in Japanese NMPC patients with ADT.
KeywordsAsian Continental Ancestry Group Bone density Gonadotropin-releasing hormone Osteoporosis Prostatic neoplasms
We thank the patients of Ogaki Municipal Hospital (Ogaki, Japan).
Compliance with ethical standards
Conflict of interest
All authors have no conflicts of interest.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. For this type of study formal consent is not required.
Informed consent was obtained from all individual participants included in the study.
- 3.Smith MR, Malkowicz SB, Chu F, Forrest J, Price D, Sieber P, Barnette KG, Rodriguez D, Steiner MS (2008) Toremifene increases bone mineral density in men receiving androgen deprivation therapy for prostate cancer: interim analysis of multicenter phase 3 clinical study. J Urol 179:152–155CrossRefGoogle Scholar
- 9.Kanis JA, on behalf of the World Health Organization Scientific Group (2007) Assessment of osteoporosis at primary health-care level. Technical Report. World Health Organization Collaborating Center for Metabolic Bone Diseases, University of Sheffield, UKGoogle Scholar
- 20.Ravn P, Cizza G, Bjarnason NH, Thompson D, Daley M, Wasnich RD, Mcclung M, Hosking D, Yates AJ, Christiansen C (1999) Low body mass index is an important risk factor for low bone mass and increased bone loss in early postmenopausal women. Early Postmenopausal Intervention Cohort (EPIC) study group. J Bone Miner Res 14:1622–1627CrossRefGoogle Scholar
- 23.Shore ND, Chu F, Moul J, Saltzstein D, Concepcion R, McLane JA, Atkinson S, Yang A, Crawford ED (2017) Polymer-delivered subcutaneous leuprolide acetate formulations achieve and maintain castrate concentrations of testosterone in four open-label studies in patients with advanced prostate cancer. BJU Int 119:239–244CrossRefGoogle Scholar